‘Liquid biopsy’ could help cancer drug response monitoring
This article was originally published in Scrip
Executive Summary
Parsortix, a blood-based diagnostic that captures and counts circulating tumor cells (CTCs) for the diagnosis, prognosis and monitoring of cancer, could be approved in around a year, according to Angle, the company developing the device. And that could mean that pharmaceutical companies have an off-the-shelf blood-based tool for monitoring and exploring the evolution of cancer cells and their response to drug treatments.